Related Experiment Video
Updated: Feb 6, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Optimizing Glioma Detection Using an EGFR-Targeted Fluorescent Affibody
Ana Luiza Ribeiro de Souza1,2, Kayla Marra1, Jason Gunn1
1Thayer School of Engineering, Dartmouth College, Hanover, NH.
Abstract:
Since many types of cancers overexpress EGFR, this surface receptor has been used as a target for therapy or diagnosis of malignant disease. Uptake kinetics of EGFR-targeted fluorescent Affibody (ABY-029) were studied with a view toward optimizing efficacy of tumor detection in a glioma as a function of both delivered dose and concurrent administration of unlabeled cetuximab (an EGFR antagonist). U251 glioma cells were inoculated in brain of nude rats, and the fluorescence from each brain was analyzed after the administration of ABY-029. Although cetuximab was able to systematically block ABY-029 binding to EGFR in a dose-dependent manner in cell culture, no influence on the tumor-to-normal brain contrast was seen when unlabeled cetuximab was administered prior to ABY-029. Ex vivo imaging of ABY-029 fluorescence showed increasing values of the tumor-to-normal brain ratio with an increasing injected dose. A saturation value was obtained at a dose of 245 μg kg-1 which represents a 10-fold increase over a "microdose" value. According to FDA, the microdose of protein products is considered ≤30 nanomoles due to its difference in molecular weight as compared to synthetic drugs. This observation indicates that glioma detection will be optimal if the ABY-029 dose exceeds the "microdose" value.
Insights
Optimizing glioma detection requires doses of fluorescent Affibody ABY-029 exceeding the FDA
Area of Science:
- Oncology
- Molecular Imaging
- Pharmacokinetics
Background:
- Epidermal Growth Factor Receptor (EGFR) is overexpressed in many cancers, making it a target for diagnosis and therapy.
- EGFR-targeted fluorescent Affibody (ABY-029) shows potential for glioma detection.
- Understanding uptake kinetics is crucial for optimizing tumor detection efficacy.
Purpose of the Study:
- To investigate the uptake kinetics of ABY-029 for glioma detection.
- To evaluate the impact of ABY-029 dose and cetuximab administration on tumor-to-normal brain contrast.
- To determine the optimal dosage for effective glioma detection using ABY-029.
Main Methods:
- U251 glioma cells were implanted in nude rats.
- Fluorescence imaging of rat brains after ABY-029 administration.
- Ex vivo imaging to analyze tumor-to-normal brain ratios at varying ABY-029 doses and with/without cetuximab.
Main Results:
- Cetuximab blocked ABY-029 binding to EGFR in cell culture but did not affect tumor-to-normal brain contrast in vivo.
- Ex vivo imaging demonstrated increased tumor-to-normal brain ratios with higher ABY-029 doses.
- A saturation value was reached at 245 μg kg⁻¹, a 10-fold increase over the microdose.
Conclusions:
- Glioma detection is optimized when ABY-029 dosage surpasses the FDA-defined microdose.
- The dose of ABY-029 is a critical factor for effective tumor visualization.
- Concurrent cetuximab administration did not enhance tumor contrast in this model.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
14:10Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Related Concept Videos
Optimal Foraging
Optimization Problems
Optimal Arousal Theory
Inverted U-Shaped Performance Curve
The...
Optimizing Chromatographic Separations
Band broadening refers to spreading solute bands as they travel through the column. This broadening can impact resolution. Plate height (H) represents the length required for one theoretical plate. A lower plate height corresponds to...
Unrealistic Optimism Bias
Targeted Cancer Therapies
There are several types of targeted therapies against...